ODAC discusses vandetanib

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA's Oncologic Drugs Advisory Committee acknowledged that there are medullary thyroid cancer (MTC) patients in whom vandetanib had an acceptable risk-benefit profile, but the committee did not vote on the issue. The panel voted 10-0 in favor of requiring a post-approval study to determine the appropriate dose to be used in patients. ...